Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Calfa

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
JCO Precision Oncology|November 21, 2022
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyKelsey A Klute, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Targeted Oncology|October 22, 2020
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyJulie G Fisher, David Tait, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology|July 16, 2024
Palbociclib in Patients With Soft Tissue Sarcoma With <i>CDK4</i> Amplifications: Results From the Targeted Agent and Profiling Utilization Registry StudyScott Schuetze, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology|January 20, 2022
Palbociclib in Patients With Non-Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyEugene R Ahn, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2021
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyAjjai S Alva, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology|February 14, 2024
Sunitinib in Patients With Breast Cancer With <i>FGFR1</i> or <i>FGFR2</i> Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry StudyCarmen J Calfa, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology|April 30, 2026
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry StudyErin F Cobain, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology|December 14, 2023
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry StudyFunda Meric-Bernstam, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2023
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry StudyHerbert L Duvivier, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology|October 16, 2024
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyFrancis P Worden, Evan Pisick, Michael Rothe, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
JCO Precision Oncology|November 21, 2022
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyKelsey A Klute, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Targeted Oncology|October 22, 2020
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyJulie G Fisher, David Tait, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology|July 16, 2024
Palbociclib in Patients With Soft Tissue Sarcoma With <i>CDK4</i> Amplifications: Results From the Targeted Agent and Profiling Utilization Registry StudyScott Schuetze, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology|January 20, 2022
Palbociclib in Patients With Non-Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyEugene R Ahn, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2021
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyAjjai S Alva, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology|February 14, 2024
Sunitinib in Patients With Breast Cancer With <i>FGFR1</i> or <i>FGFR2</i> Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry StudyCarmen J Calfa, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology|April 30, 2026
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry StudyErin F Cobain, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology|December 14, 2023
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry StudyFunda Meric-Bernstam, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2023
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry StudyHerbert L Duvivier, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology|October 16, 2024
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyFrancis P Worden, Evan Pisick, Michael Rothe, et al.
Pageof 3